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Abstract
Objectives
The objective of this study was to evaluate the cost-effectiveness of abatacept, tocilizumab,
and tumor necrosis factor (TNF) inhibitors as compared with rituximab in Finnish rheumatoid
arthritis patients, who have previously been treated with TNF inhibitors.
Methods
A patient-level simulation model was developed to predict costs and outcomes associated
with four biological drugs (abatacept, tocilizumab, rituximab and TNF inhibitors) in the treat-
ment of rheumatoid arthritis. Following lack of efficacy or adverse events, the patients were
switched to another biological drug until all four options were exhausted. After that, the
patients were assumed to receive a 6th line treatment until death. The patients’ baseline
characteristics and regression models used in the simulation were based on observational
data from the National Register for Biological Treatments in Finland. Direct costs comprised
drug costs, administration costs, costs of switching, and outpatient and inpatient care, while
indirect costs included disability pension and sick leaves due to rheumatoid arthritis. Several
subgroup and deterministic sensitivity analyses were conducted.
Results
Drug costs were the lowest for rituximab, but when administration costs and costs of switch-
ing were included, drug costs were the lowest for TNF inhibitors. Abatacept was associated
with the highest drug costs, whereas rituximab was associated with the highest healthcare
costs. In total, TNF inhibitors had the lowest direct costs, while rituximab had the highest
direct costs. The amount of quality-adjusted life years (QALY) gained ranged from 9.405 for
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rituximab to 9.661 for TNF inhibitors. TNF inhibitors, abatacept, and tocilizumab were domi-
nant in comparison to RTX.
Conclusions
TNF inhibitors, abatacept, and tocilizumab had lower costs and higher QALYs than rituxi-
mab, and therefore, they were dominant in comparison to rituximab. As TNF inhibitors had
the lowest costs and highest QALYs, they were the most cost-effective treatment option.
Introduction
Rheumatoid arthritis (RA) causes significant costs for society due to the increased use of
healthcare resources, sick leaves and early retirements. Consequently, effective anti-rheumatic
therapies have the potential to reduce societal costs while also improving the patients’ quality
of life. According to current Finnish Care Guideline, treatment of RA should be initially
treated with a combination of methotrexate (MTX), hydroxychloroquine (HCQ), sulfasalazine
(SSZ) and a low-dose glucocorticoid [1]. In case of an insufficient response or intolerance, bio-
logical disease modifying anti-rheumatic drugs (bDMARDs), i.e. abatacept (ABA), tocilizumab
(TCZ), rituximab (RTX), sarilumab (SAR), and tumour necrosis factor (TNF) inhibitors
including etanercept (ETN), adalimumab (ADA), infliximab (IFX), certolizumab pegol (CTZ),
and golimumab (GOL) are prescribed [1,2]. The bDMARDs have comparable efficacy and not
significantly differing safety profiles [1,3–7]. bDMARDs are recommended to be used in com-
bination with methotrexate rather than as monotherapy due to better efficacy and reduced
immunogenicity. However, ABA and TCZ as monotherapy have been shown to have similar
efficacy as in combination with MTX [8,9].
A previously published systematic review indicated RTX as the most cost-effective
bDMARD among patients with an insufficient response to bDMARD treatment [10]. Previous
cost-effectiveness analyses were mostly based on the efficacy measured in randomized con-
trolled trials (RCT), and might therefore, have limited generalizability to routine healthcare
owing to stringent inclusion criteria and brief follow-up [11]. Nevertheless, a previous study
based on observational data showed RTX to provide small savings and quality-adjusted life
year (QALY) gains as a second line treatment as compared with TNF inhibitors [12]. Whether
these findings are generalizable to Finnish healthcare is unknown. Also, introduction of biosi-
milars has lowered the treatment costs of some TNF-inhibitors as well as rituximab. The treat-
ment of RA, especially in the field of biological drugs, has changed a lot during previous years,
and therefore, there is a need for cost-effectiveness analyses based on real-world data reflecting
current treatment practice and providing valuable information for health-care decision mak-
ing. The objective of this study was to evaluate the cost-effectiveness of ABA, TCZ, and TNF
inhibitors as compared with RTX in RA patients, who have previously been treated with TNF
inhibitor using Finnish patient-level registry data.
Materials and methods
Model structure
We developed a patient-level simulation model using R statistical programming language 3.2.2
to estimate costs and outcomes associated with different bDMARDs in the treatment of RA.
The population consisted of RA patients who had previously used a TNF inhibitor as their first
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bDMARD and were about to begin their second bDMARD. The model simulated four alterna-
tive treatment regimens: ABA, RTX, TCZ and a second TNF inhibitor. In this simulation TNF
inhibitors were considered together as a single group rather than as individual drugs due to
the same mechanism of action and similar effectiveness [11,13]. Different routes of adminis-
tration for ABA and TCZ were also pooled as single groups. In the base case analysis, the
choice of admin route of ABA and TCZ was based on the National Register for Biologic Treat-
ment in Finland (ROB-FIN). Every treatment regimen was simulated by identical cohorts of
1,000 patients. In case the simulated bDMARD treatment was discontinued either due to lack
of efficacy or adverse events, patients were switched to another bDMARD in the beginning of
the next cycle until the patient had exhausted all four treatment options [14–16]. After that,
patients were assumed to be treated with a 6th line treatment until death. The outline of the
model is presented in Fig 1.
Patients were assumed to remain on any given treatment for at least 6 months. At the end
of each six-month period, the model individually evaluated for each person whether he or she
would continue treatment, discontinue it or die. The length of the time period was set to six
months as this was the average time interval for routine care visits to rheumatologists in the
(ROB-FIN).
The simulation used regression models to predict outcomes and costs for each patient indi-
vidually in each period (S1 Fig). Each patients’ characteristics, history of drug use and past
treatment responses were recorded in the model and utilized as predictors for future outcomes
and costs. The analysis was conducted from a societal perspective as the study included both
direct and indirect costs. Half-cycle correction was applied to both outcomes and costs. We
analyzed direct costs and both direct and indirect costs separately [17]. Health outcomes also
were expressed as QALYs. Based on the Finnish recommendations for health economic evalu-
ations, all costs and benefits were discounted at 3.0% annually [17]. Primary outcome of the
simulation was incremental cost-effectiveness ratio (ICER) per QALY including only direct
costs.
Fig 1. Treatment pathways included in the model. The pathways for rituximab, tocilizumab and TNF-inhibitors follow identical logic as for abatacept.
DAS28 = Disease Activity Score 28, HAQ = Health Assessment Questionnaire, TNF inhibitor = tumor necrosis factor inhibitor.
https://doi.org/10.1371/journal.pone.0220142.g001
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Data sources
Primary data source for the model was the ROB-FIN and all assumptions were based on
observed data unless otherwise mentioned. ROB-FIN has been described in previous publica-
tions [11,18–20]. In brief, ROB-FIN is a longitudinal observational cohort study established in
1999 to monitor effectiveness and safety of biologic drugs in treatment of RA and was origi-
nally based on structured data collection forms submitted by rheumatologists on patients´ rou-
tine care visits to outpatient specialized healthcare. Starting in 2007, most of the data have
been retrieved from electronic patient monitoring systems. Additional data on the patients’
hospitalization and outpatient visits as well as sick leaves and disability pensions were acquired
from national healthcare registers, which were linked to ROB-FIN using social security
numbers.
Observed ROB-FIN data from baseline visit as well as subsequent follow-up visits were
used to construct the regression models later used to predict patients’ treatment response, util-
ity and costs in the simulation. Independent variable selection for the regression models was
based on Akaike Information Criteria although the choice of bDMARD therapy and its inter-
actions with other variables were always included where appropriate. Missing data among dis-
ease activity parameters were imputed by multiple imputation whereas information on
treatments and use of healthcare resources were considered complete. Patients lost to follow-
up were treated as uninformative censoring while information on treatment discontinuations
were utilized in the modeling.
Model inputs
Baseline characteristics. The model population were sampled with replacement among
the patients included in ROB-FIN about to start their second bDMARD therapy thus preserv-
ing any potential correlation between the variables. The baseline variables included in the
model comprised age, sex, weight, Body Mass Index (BMI), Health Assessment Questionnaire
(HAQ), DAS28, time from diagnosis of rheumatic disease, Rheumatoid Factor (RF) status,
and concomitant use of MTX, SSZ and HCQ along with the patients’ healthcare costs during
the past 12 months. The patients´ weight, BMI and RF status were fixed at the baseline values.
Clinical effectiveness. Treatment effectiveness was defined as an achievement of at least
American College of Rheumatology (ACR) 20% improvement, a moderate European League
Against Rheumatism (EULAR) response, or a Disease Activity Score 28 (DAS28) value of less
than 3.2 [14–16]. The actual observed data were used to construct regression models, which in
turn were used to predict the responses in the simulation. Based on expert opinion, the treat-
ment response to the 6th line treatment options was assumed to be the same as averaged treat-
ment response to all biological treatments in the model.
The patients’ underlying HAQ score was assumed to remain fixed at the baseline value. The
change in HAQ score in comparison to baseline was modeled and subsequently predicted
using a linear regression model. Any effect the treatment could have on these disease activity
parameters was assumed to be temporary and re-evaluated in the next period.
Clinical safety. In addition to lack of efficacy, treatment might be discontinued due to
adverse events and other reasons. The risk of discontinuation due to adverse events and other
reasons besides lack of efficacy was observed to be 0.068 across all bDMARDs in average based
on the available data in ROB-FIN. After every six-month time period 0.017, 0.010 and 0.009
per cent of MTX, SSZ and HCQ users discontinued the use of the said co-treatment,
respectively.
Mortality. Mortality rate adjusted by age and sex for patient-level data was based on the
life table in 2017 published by Statistics Finland [21]. In this model, RA was associated with
Cost-effectiveness of biological drugs in rheumatoid arthritis
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mortality of general population [22–24]. Despite using lifetime horizon in the model, we
assumed that patients would die at the latest at the age of 100 due to lack of mortality data
beyond that age.
Utility. Quality-adjusted life years (QALY) were calculated corresponding to EuroQol
five dimensions questionnaire (EQ-5D-3L) utilities predicted from the HAQ scores utilizing a
multinomial logistic regression model. The regression model was based on data from a survey
including both HAQ and EQ-5D-3L conducted in Finland in 2009 [20]. Obtained EQ-5D-3L
health stages were valued with the Finnish tariff [25].
Costs. Direct costs comprised drug costs, administration costs of infusions, costs of
switching, outpatient and inpatient care, while indirect costs included early retirement due to
RA and sick leave. Costs of drugs were based on the Finnish price list including the retail price
without value added tax of drugs and the dose in the label [26]. The costs for infusion drugs
were the wholesale prices of Helsinki and Uusimaa Hospital District (Aaltonen T, personal
communication, April 20, 2016). The prices of biosimilar IFX, ETN, and ADA were used in
the base case analysis, whereas the price of biosimilar of RTX was taken into account in sensi-
tivity analysis. Administration costs of infusions including intravenous treatment cost prices
of bDMARDs for RA at Finnish hospitals were derived from the Finnish study by Soini et al
[27]. The price for TNF inhibitor group was an average for individual TNF inhibitors weighed
by their actual usage. Similarly, the costs for ABA and TCZ were weighed averages based on
the prices of subcutaneously and intravenously administered products. In the base case analy-
sis, the bDMARD was subcutaneously administered for 15 and 7 per cent of ABA and TCZ
users, respectively. Drug costs, administration costs of infusions and dosages are presented in
S1 Table. Cost of switching was assumed to be equal to the cost of one healthcare visit to inter-
nal medicine specialist in specialized outpatient healthcare [28]. Based on the expert opinion
and in line with their effectiveness, the costs of the 6th line treatment option were considered
to be same as the averaged costs of currently available biological treatments.
Patients’ biannual healthcare and indirect costs were modeled using a linear regression
model based on actual observed data and later predicted in the simulation using this model.
Drugs in outpatient care were in 2019 euros and all other costs were converted to 2017 euros
using the price indices of Statistics Finland [29].
Sensitivity analyses
The model was stochastic in nature and the 1000 unique model runs with different seeds for
random number generator quantified the variability in the results. Several subgroup and deter-
ministic sensitivity analyses were carried out based on 300 model runs to explore uncertainty
and heterogeneity of the model results. As ABA and TCZ can be administered either subcuta-
neously or intravenously, we evaluated the influence of the choice of the administration route
on the results in the deterministic sensitivity analyses. Even though HAQ progression was
associated with age and the number of biologic treatment in the base case analysis, we used
annual HAQ progression rates of 0.03 and 0.06 in the sensitivity analyses [30]. Also, we
included a scenario where we employed a British tariff to value EQ-5D health stages [31].
Although the patent of RTX has expired, RTX biosimilar approved for the treatment of RA is
not on the market in Finland. Therefore, we considered RTX biosimilar with a price discount
of 30% in comparison to the reference medicinal product in sensitivity analysis. The time hori-
zon of 10 years and the discounting rate of 0% and 6% were explored in the sensitivity analyses
[17]. In subgroup analyses we evaluated the heterogeneity of the results related to the use of
the concomitant csDMARD therapy, age, body mass index (BMI), gender, presence of RF,
prior use of MTX, and primary response to the first TNF inhibitor.
Cost-effectiveness of biological drugs in rheumatoid arthritis
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Ethical approval
Ethical approval for this study was granted by the Helsinki University Central Hospital ethical
committee (73/13/03/00/2014). The study permit to use the patient records and cost data was
granted by the Finnish National Institute for Health and Welfare (THL/1497/.5.05.00/2013),
Finnish Population Registry (262/410/16) and the Social Insurance Institution of Finland
(Kela 7/522/2016). Written informed patient consents were acquired from patients who had
been included in ROB-FIN prior to the introduction of the electronic patient monitoring
systems.
Results
Baseline characteristics
At baseline, median age of patients included in the study was 56 years (Table 1). Most of the
patients were female. Median HAQ score was 1.1, whereas median DAS28 was 4.6. More than
half of the patients had a treatment response to the first TNF inhibitor. The characteristics of
the patients at the baseline are presented in Table 1.
Base-case analysis
Lifetime drug costs without administration costs and costs of switching were the lowest for
RTX, but when administration costs and costs of switching were included, drug costs were the
lowest for TNF inhibitors (Table 2). ABA had the highest drug costs. However, ABA had the
lowest healthcare costs, while RTX had the highest healthcare costs. In total, the lowest and
highest direct costs were associated with the TNF inhibitors and RTX, respectively. Indirect
costs ranged from 148,718 € for TNF inhibitors to 165,300 € for RTX. Drug costs including
administration costs and costs of switching represented over half of the total costs. QALYs ran-
ged from 9.405 of RTX to 9.661 of TNF inhibitors. In our model, patients died in average at
the age of 85.59 (standard deviation 9.96).
TNF inhibitors, ABA, and TCZ had lower costs and higher QALYs than RTX, and there-
fore, they were dominant in comparison to RTX (Table 3 and Fig 2). TNF inhibitors are the
Table 1. Characteristics of the patients at the baseline.
Variable Median / % The first and the third quartile / n
Age (years) 56 47–63
Male 25 361
Weight 72 65–82
BMI (kg/m2) 26 24–28
DAS28 4.6 3.5–5.7
HAQ 1.1 0.6–1.6
Methotrexate 55 786
Hydroxychloroquine 27 384
Sulfasalazine 18 257
Patients with positive rheumatoid factor status 92 1,306
Patients with response to the first TNF inhibitor 65 922
Time from the diagnosis of rheumatoid arthritis (years) 13 7.3–20
Outpatient and inpatient care costs during the last 6 months (€) 1,737 890–4,561
Outpatient and inpatient care costs during the last 12 months (€) 3,542 1,601–7,723
BMI = body mass index, DAS28 = Disease Activity Score 28, HAQ = Health Assessment Questionnaire, TNF
inhibitor = tumor necrosis factor inhibitor
https://doi.org/10.1371/journal.pone.0220142.t001
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most cost-effective treatment option, as they have the lowest costs and the highest lifetime
QALYs.
Sensitivity analysis
The results regarding costs and QALYs from the subgroup and deterministic sensitivity analy-
sis are presented in S2 and S3 Tables. Instead of intravenous administration, the use of self-
administered ABA and TCZ decreased the administration costs of drugs, but the choice of
route of administration had no effect on other costs. Similarly to base case results, RTX had
the highest costs and lowest QALYs when they were discounted at 0%, but when the discount-
ing rate of 6% was used, TCZ had the lowest QALYs. When the time horizon of 10 years was
used, RTX had the lowest drug costs including the costs of switching and the administration
costs, while TCZ was associated with the lowest QALYs. As compared with RTX, TNF inhibi-
tors were dominant, whereas the incremental cost-effectiveness ratio for ABA was 144,213
€/QALY when the time horizon of 10 years was used. RTX as a second-line treatment option
had the highest direct costs even when the price discount of 30% for RTX biosimilar was used,
owing to the highest outpatient and inpatient costs for RTX. Indirect costs increased and
QALYs decreased in case the bi-annual HAQ progression was fixed at 0.03 or 0.06. Removing
half-cycle correction had little effect on the results. QALYs decreased when the health stages
were valued with the British tariff. The costs were higher and QALYs were lower for women
Table 2. Lifetime costs and QALYs of bDMARDs per patient as a second-line biologic therapy in rheumatoid arthritis. All costs and QALYs were discounted at 3%
per year.
Abatacept Tocilizumab TNF inhibitors Rituximab
Drug costs, € 211,384 211,071 201,436 201,407
Administration costs, € 57,799 56,983 47,656 48,908
Drug costs including administration costs and costs of switching, € 270,028 268,928 249,937 251,291
Outpatient and inpatient costs, € 25,805 32,749 26,968 69,681
Direct costs, € 295,833 301,677 276,905 320,972
Indirect costs, € 154,293 159,480 148,718 165,300
Total costs, € 450,126 461,157 425,623 486,272
Life years 19.271 19.271 19.272 19.272
QALYs 9.475 9.407 9.661 9.405
bDMARD = biological disease-modifying anti-rheumatic drug, QALY = Quality-adjusted life year, TNF inhibitor = tumor necrosis factor inhibitor
https://doi.org/10.1371/journal.pone.0220142.t002
Table 3. Lifetime cost-effectiveness of bDMARDS in comparison to rituximab as a second-line biologic therapy in rheumatoid arthritis. All costs and QALYs were
discounted at 3% per year.
Abatacept vs. rituximab Tocilizumab vs. rituximab TNF inhibitors vs. rituximab
Incremental costs, € (only direct costs) -25,139 -19,295 -44,067
Incremental costs, € (both direct and indirect costs) -36,145 -25,115 -60,649
Incremental life years -0.00090 -0.00059 -0.00006
Incremental QALYs 0.070 0.002 0.256
ICER, €/QALY (only direct costs) Dominant Dominant Dominant
ICER, €/QALY (both direct and indirect costs) Dominant Dominant Dominant
bDMARD = biological disease-modifying anti-rheumatic drug, ICER = Incremental cost-effectiveness ratio, QALY = Quality-adjusted life year, TNF inhibitor = tumor
necrosis factor inhibitor
https://doi.org/10.1371/journal.pone.0220142.t003
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than for men. As compared with patients with no response to the first TNF inhibitor, primary
responders had slightly higher costs and QALYs. The QALYs ranged from 11.960 to 12.370 for
patients with negative RF status, while QALYs ranged from 9.159 to 9.415 for patients with
Fig 2. Incremental cost-effectiveness planes and cost-effectiveness acceptability curve for abatacept, TNF inhibitors, and tocilizumab in comparison to rituximab
for the treatment of rheumatoid arthritis as a second-line therapy in a lifetime scenario. ICER = incremental cost-effectiveness ratio, QALY = quality-adjusted life
year, TNF-inhibitors = tumor necrosis factor inhibitors.
https://doi.org/10.1371/journal.pone.0220142.g002
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positive RF status. Also the costs were higher among patients with negative RF status as com-
pared to RF-positive patients. Furthermore, concomitant use of MTX or other non-biologic
therapies lead to increased QALYs in comparison to non-use of MTX or biologic monother-
apy, respectively.
Discussion
Based on our patient-level simulation model using real-world data from Finland, TNF inhibi-
tors, ABA, and TCZ as a second-line biologic treatments for RA were dominant as compared
with RTX. Even though a commonly referred threshold for cost-effectiveness has not been
published in Finland, we have used the willingness to pay threshold of 40,600€, representing
the Finland´s gross domestic product per capita in 2017 per QALY gained in this study. [32]
According to our model, RTX was associated with the lowest drug costs, but when administra-
tion costs and costs of switching were included, TNF inhibitors had the lowest drug costs.
RTX had the highest healthcare costs, and in total, RTX was associated with the highest drug
costs. TCZ was associated with the lowest effectiveness. TNF inhibitors had the lowest costs
and the highest QALYs, and therefore, they were the most cost-effective treatment option.
Consistent with our results, previous studies showed similar effectiveness between
bDMARDs in patients with RA failing on TNF inhibitor [33,34], whereas other studies suggest
that changing to RTX is more effective than switching to an alternative TNF inhibitor [35,36].
Unlike our results, previously published results by Lindgren et al. found that RTX treatment
was associated with the lowest overall costs and was the most effective option [12]. Similarly,
in a head-to-head RCT between RTX, TNF-inhibitors, ABA and TCZ, RTX was associated
with both the lowest costs and the highest QALY gain [37]. The Finnish study reported also
RTX to be most cost-effective treatment alternative for patients with RA who have failed TNF
inhibitor treatment [38]. According to this study, life years were highly similar between all
bDMARDs, but they were the highest for RTX.
The main advantage of this study was that real-world data on costs and effectiveness were
based on registry data from the same population. Baseline characteristics of the model and
population and the assumptions used in the model were mainly based on ROB-FIN data repre-
senting routine clinical practice. Compared to the previous studies mostly based on efficacy
derived from RCTs, our simulation was based on observational data and therefore results are
likely to be more generalizable to the Finnish healthcare setting [11]. In addition, cost data
derived from comprehensive Finnish national registers were employed whenever possible. To
eliminate the bias caused by confounders in the observational data, we used several regression
models to predict the patients’ treatment response, utility and costs in the simulation.
Our model memorized changes in patient characteristics over time and enabled simulation
based on individual patients’ history. The history of what had happened was an important
aspect of the model because it affected the occurrence of future events, their consequences and
valuations, and many other aspects of the simulation. The simulation followed up patients for
their complete lifetime, because RA is a chronic disorder that progresses over time. As such,
long-term consequences of any differences in disease progression, effect on life expectancy, or
drug discontinuation rates were assessed. The first TNF inhibitor was not included in this
model as it was assumed to be identical between the comparators and would not affect the
results. Reasons for discontinuation of RTX treatment were severely underreported in ROB-
FIN data and therefore, the risk of adverse events was assumed to be equal across all treatment
regimens. Also, the discontinuation probabilities for non-biologic co-therapies were assumed
to be similar between the users of different biologics.
Cost-effectiveness of biological drugs in rheumatoid arthritis
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Because of high costs of original bDMARDs, interest has grown in biosimilars that are com-
parable to the reference medicinal product in terms of efficacy and safety. Many original bio-
logic drugs have reached, or are approaching, patent expiry. This will lead to increasing
development and use of biosimilar drugs in the future, offering considerable savings in com-
parison with the reference medicinal product. Price competition after patent expiry may also
reduce the price of reference medicinal product, leading to remarkable cost savings. Biosimi-
lars of ETN, IFX, and ADA were considered in this analysis. The price of RTX biosimilar used
for the treatment of RA was not available, but we used price discount of 30% for RTX biosimi-
lar in the sensitivity analysis based on the Finnish legislation concerning the confirming a rea-
sonable wholesale price for medicinal products [39]. However, the price discount may be even
bigger in the future.
A potential limitation of this study is related to the dosing interval of RTX. As compared
with other biologics, RTX has a unique mode of action and long dosing interval. In mainte-
nance treatment, RTX infusions were often administered on demand in Finland. Conse-
quently, the patients treated with RTX came to visit the rheumatologist only after the effect of
the previous infusion began to wear off, which is very likely to lead to an underestimation of
the effectiveness of RTX in our data, and therefore, leading to overestimation of healthcare
costs. Based on the registry data used in this study, RTX was administered every 7.98 months
in maintenance treatment. Similar dosing interval of RTX was reported by Keystone et al [40],
whereas mean dosing interval of RTX varied between 11 and 13 months in daily clinical prac-
tice in Finland according to the study by Valleala et al [41]. Therefore, a relatively short dosing
interval used in this study might also be one reason to cause high costs of RTX treatment. In
this model RA was associated with mortality of general population, which is another limitation
of this study. According to the study by Kroot et al, mortality of RA patients was comparable
with the expected mortality of the general population of the Netherland up to 10 years of RA
[23]. This finding was in line with the study by Lindgqvist and Eberhardt et al. [24]. Further-
more, Lacaille et al found that mortality gap between RA and the general population in the
first five years was not observed in people with RA onset after year 2000 [22]. However, it is
notable that the patient populations in these studies comprised of patients with recent onset of
RA. Although mortality has decreased among RA patients over the past decades, the general
belief is that patients with RA, especially the more severe cases, have a shortened life expec-
tancy compared with the general population [42]. We assume that differences in QALYs
between bDMARDS would have been bigger, but the order of these results would have been
the same, if the association between disease activity and mortality in RA patients had been con-
sidered in the model. We did not however, have sufficient data to create a prediction model
for mortality, which can be considered a limitation. Furthermore, patients’ erosive progression
could not be taken into account as data on this subject was not available in ROB-FIN. The
effect could be mitigated by inclusion of HAQ scores, which have been shown to be correlated
with the presence of joint erosions [43]. Some bias could also be caused by the lack of a generic
health related quality of life instrument. When we employed another valuation method in sen-
sitivity analysis, the QALYs decreased when health stages were valued with the British tariff.
Conclusion
Our patient-level simulation based on observational data showed that TNF inhibitors were
associated with the lowest costs and highest QALYs, whereas RTX had the highest costs and
lowest QALYs. TNF inhibitors, ABA, and TCZ were dominant in comparison to RTX. As
TNF inhibitors had the lowest costs and highest QALYs, they were the most cost-effective
treatment option.
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